Emerging studies suggest Retatrutide , a dual agonist targeting both the gut-brain axis and GIP , may offer a significant step forward for body management . Early patient tests have shown considerable reductions in body mass , potentially surpassing existing body composition therapies . Nevertheless , additional assessment is needed to thoroughly d